Identification of the first succinate receptor agonists

  The succinate receptor (formerly GPR91 or SUCNR1) is expressed in a variety of tissues, including blood cells, adipose tissue, the liver, retina, and kidney. Although its function remains to be established in most tissues, it has recently emerged as novel mediator in local stress situations, including in immune responses and inflammation, retinal angiogenesis and […]

HIMSS Liège Congress: the Continuity of Care Maturity Model

The University Hospital of Liège (CHU de Liège), the University of Liège (ULg) and the HIMSS French Community organize an eHealth event, HIMSS Liège, on March 28th and 29th 2017 at ULg, Place du 20 Août 7, 4000 Liège. The program of the event will be based on the HIMSS Continuity of Care Maturity Model […]

The University of Liège receives funding from the Interreg V-A programme (Greater Region) for the development of new bioMaterials for PROliferation and in vitro Expansion of STEM cells (Improve-Stem)

The Laboratory of Chemical Engineering (Pr. D. TOYE) and the Interfaculty Center for Biomaterials (C. GRANDFILS) from the University of Liège together with the University of Kaiserslautern, the Luxembourg Institute of Science and Technology (LIST), the Leibniz Institute for New Materials (INM), the University of Lorraine and the National Center for Scientific Research (CNRS) bring up keys […]

First results of the BIOCYCLE project will be presented during the ECCO’17 Congress in Barcelona on February 15th, 2017

This project, funded by the European commission under the Horizon 2020 program, aims at exploring different aspects of the question of treatment de-escalation in moderate-severe Crohn’s disease (CD), first requiring a combination therapy with anti-TNF and antimetabolites to control the disease. The global aim of BIOCYCLE is to try and bring an integrated multidimensional and […]

Led by B2H, the CHU de Liège and the ULg have launched their collaboration with Janssen Pharmaceutica

The University of Liège (ULg), the Centre Hospitalier Universitaire (CHU) de Liège, Janssen Pharmaceutica and Janssen-Cilag have signed on February 2nd a charter to launch their collaboration, aiming at strengthening their mutual competences in the setting-up and execution of multidisciplinary research projects and thus, accelerating patient access to medical innovations. The objective is to promote […]

The GIGA awarded with an European grant from Infect-Era

The GIGA has been recently awarded with an European grant from the 4th call of the Infect-Era. The laboratory of Emmanuel Dejardin, together with research groups from France (Fabien Zoulim, CRCL, and François-Loïc Cosset, CIRI) and Germany (Mathias Heikenwalder, Heidelberg), is involved in a project called Target-HDV. HDV (Hepatitis Delta Virus) super-infection of chronically HBV-infected […]

A new unit for the CHU Liège Toxicology Department to better serve the pharma sector

ATC is a contract research organisation (CRO) with its facilities based within the CHU Liege. Its flexibility and multidisciplinary expertise, its access to patients via its privileged contacts with CHU medical departments and its links to ULg research centres are key factors determining its consistent success over the last third of a century. As of […]

CHU-ULg-Janssen Pharmaceutica Collaboration agreement

The CHU of Liège, the University of Liège and Janssen Pharmaceutica NV launch a collaboration initiative on promising medical projects. A collaborative charter will be signed on Thursday February 2nd, 2017. Further information on the event are available here  

New Opportunity

A new opportunity is available, namely “Continuous-flow process for the preparation of methylphenidate hydrochloride”. For more information, please click here